[Long-term assessment of bone loss in patients treated with GnRH agonists].
GnRH Analogues therapy of estrogen-dependent gynaecological diseases aims at suppression of physiologic ciclic ovaric function producing a hypogonadotropic condition. The first consequence of GnRH Analogues administration is hypoestrogenism; this condition permits the disease regression but, on the other, it causes a negative impact on bone metabolism particularly for prolonged therapeutic schemes (6 months). This study has evaluated the faculty of bone mass protection combining GnRH Analogues therapy with Ipriflavone that stimulates, both "in vivo" and "in vitro", Osteoblastic cells activity. The result of this study showed a significant bone loss in patients treated with GnRH Analogues only. The Ipriflavone association prevented bone loss.
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001862:Bone Resorption / Q000139:chemically induced / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000627:therapeutic use*; D016729:Leuprolide / Q000009:adverse effects*
D018931:Antineoplastic Agents, Hormonal; D007529:Isoflavones; C018986:ipriflavone; D016729:Leuprolide
Valutazione a lungo termine della perdita calcica ossea nelle pazienti trattate con GnRH Agonisti.